ProCE Banner Activity

HBV Vaccination in People With HIV

Clinical Thought

As the use of 2-drug antiretroviral therapy regimens for HIV treatment continues to increase, so does the importance of ensuring that our patients have adequate HBV immunity. This highlights the significance of an IDWeek 2022 presentation evaluating the recently approved HepB-CpG vaccine in people with HIV.

Released: November 22, 2022

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Merck, ViiV Healthcare; researcher: Gilead Sciences, Janssen, ViiV Healthcare.